Credit: Shutterstock
December 19, 2023 11:24 AM ESTUpdated December 20, 03:14 PM
R&D
In Focus

Lil­ly, No­vo’s bet on heart dis­ease starts to take shape, and 2024 could be a piv­otal year for their GLP-1s 

Max Gelman

Senior Editor

Eli Lil­ly and No­vo Nordisk are steadi­ly — and some­what qui­et­ly — prepar­ing to build com­pre­hen­sive car­dio­vas­cu­lar fran­chis­es helmed by their lu­cra­tive treat­ments for di­a­betes and obe­si­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times